Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04593043 · ClinicalTrials.gov registry record
Replication of the RELY Anticoagulant Trial in Healthcare Claims Data
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 78,140
- Enrollment target
NCT04593043: Completed study, sponsored by Brigham and Women's Hospital.
NCT04593043 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 78,140 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04593043 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 78,140 participants
- Enrollment target
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Primary Outcome
Relative hazard of composite outcome of Stroke and Systemic Embolism - Please refer to uploaded protocol for full definition due to size limitations.
Interventions
- DRUG Warfarin
- DRUG Dabigatran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78,140 participants |
| Start Date | 2020-01-01 |
| Est. Completion | 2021-02-18 |
What the finished NCT04593043 record still lists
NCT04593043 is an observational study that tracks outcomes without assigning an intervention. Its 78,140 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Warfarin is the first listed.
NCT04593043 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04593043 about?
NCT04593043 is a clinical study titled "Replication of the RELY Anticoagulant Trial in Healthcare Claims Data". Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such...
What is the current status of trial NCT04593043?
This trial is currently completed. The enrollment target is 78,140 participants. The study started on 2020-01-01. Estimated completion is 2021-02-18.
What interventions are being tested in trial NCT04593043?
The interventions under investigation include: Warfarin (DRUG), Dabigatran (DRUG).
Who is sponsoring clinical trial NCT04593043?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00063063 · 80,000 participants
Generic Database of Very Low Birth Weight Infants
- NCT06625983 · 80,000 participants · NA
Use of a Colorectal Cancer Screening Decision Support Tool in Primary Care
- NCT05701111 · 80,800 participants · NA
Building Resilience at Schools: Emotional and Biological Assessment and Treatment of Traumatic Stress
- NCT02402244 · 75,000 participants
Project: Every Child for Younger Patients With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI